Related references
Note: Only part of the references are listed.Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Jing Pan et al.
BLOOD (2020)
Multifaceted characterization of the signatures and efficacy of mesenchymal stem/stromal cells in acquired aplastic anemia
Jiali Huo et al.
STEM CELL RESEARCH & THERAPY (2020)
SnapShot: Natural Killer Cells
Adeline Crinier et al.
CELL (2020)
High-efficient generation of VCAM-1+mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice
Yimeng Wei et al.
CELL PROLIFERATION (2020)
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease
Qinjun Zhao et al.
STEM CELL RESEARCH & THERAPY (2019)
Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma
Lihui Zhuang et al.
HEPATOLOGY INTERNATIONAL (2019)
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
May Daher et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells
Inigo Terren et al.
FRONTIERS IN IMMUNOLOGY (2018)
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming
Cristina Capuano et al.
FRONTIERS IN IMMUNOLOGY (2018)
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
Yuan Hu et al.
ACTA PHARMACOLOGICA SINICA (2018)
Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials
Wade Chun-Wai Suen et al.
CANCER INVESTIGATION (2018)
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
Stephan Kloss et al.
HUMAN GENE THERAPY (2017)
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
Markus Granzin et al.
FRONTIERS IN IMMUNOLOGY (2017)
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Petra S. A. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies
Michael Boeckh et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
A novel method to expand large numbers of CD56+ natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation
Sumithira Vasu et al.
CYTOTHERAPY (2015)
Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage
Andre Cohnen et al.
BLOOD (2013)
Irradiated and Activated Autologous PBMCs Induce Expansion of Highly Cytotoxic Human NK Cells In Vitro
Yong-Oon Ahn et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Natural killer cells: a review of manufacturing and clinical utility
Scott A. Koepsell et al.
TRANSFUSION (2013)
Bringing natural killer cells to the clinic: ex vivo manipulation
Richard W. Childs et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
Tolga Sutlu et al.
CYTOTHERAPY (2010)
Natural killer cell-directed therapies: moving from unexpected results to successful strategies
Magali Terme et al.
NATURE IMMUNOLOGY (2008)
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience
D. H. McKenna et al.
TRANSFUSION (2007)